Advocacy intelligence hub — real-time data for patient organizations
Medstar Health Research Institute — NA
Innovent Biologics (Suzhou) Co. Ltd. — PHASE3
Jiangsu Alphamab Biopharmaceuticals Co., Ltd — PHASE3
Qilu Hospital of Shandong University — PHASE2
Sichuan Cancer Hospital and Research Institute
Radboud University Medical Center
Uppsala University Hospital
Daiichi Sankyo — PHASE2, PHASE3
Memorial Sloan Kettering Cancer Center — PHASE2
Avenzo Therapeutics, Inc. — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance14
VITRAKVI
Bayer
ALECENSA
Genentech
IMFINZI
AstraZeneca
Tecentriq Hybreza
Genentech
TECENTRIQ
Genentech
Gefitinib
AstraZeneca
Rozlytrek
Genentech
IRESSA
AstraZeneca
Lorbrena
Pfizer
TAGRISSO
AstraZeneca
ZYKADIA
Novartis
TEPADINA
Adienne
HYRNUO
Sandoz
KEYTRUDA
Merck
Avastin
(bevacizumab)Orphan drugGenentech, Inc.
Vascular Endothelial Growth Factor Inhibitor [EPC]
12.1 Mechanism of Action Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial ce...
Oncoscint CR/OV
(Satumomab pendetide)Orphan drugstandardCytogen Corporation
Rubraca
(rucaparib)Orphan drugstandardpharma&
12.1 Mechanism of Action Rucaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3, which play a ...
Global Clinical Leader
Daiichi Sankyo
Elizabeth M. Swisher
Fred Hutch/University of Washington Cancer Consortium
📍 SEATTLE, WA
David M Gershenson, M.D
NRG Oncology
📍 HOUSTON, TX
Amir A. Jazaeri, MD, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
John K Chan
NRG Oncology
Don Dizon, MD
NRG Oncology
📍 PROVIDENCE, RI